Cellarity is transforming drug discovery by seeking to understand health and disease at a cellular level rather than looking for molecular targets for medicines. The company is harnessing a confluence of technologies to understand cellular changes that underlie disease and develop medicines that can restore them to healthy function. It now has programs in metabolic disease, hematology, immune-oncology and respiratory disease, a reflection of the broad applicability of its approach. We spoke to Fabrice Chouraqui, CEO of Cellarity, about the company’s to drug discovery, the technology it is harnessing, and why focusing on cells rather than molecular targets are a better way to discover drugs.
